Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)
Official title: Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2016-01-01
Completion Date
2028-12-31
Last Updated
2024-04-05
Healthy Volunteers
No
Interventions
Cytoreductive prostatectomy or brachytherapy
local treatment+SOC for metastatic prostate cancer
ADT+second-generation antiandrogens ± chemotherapy
SOC(Triplet or doublet therapy) for mHSPC
Locations (1)
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China